Altered PI3-kinase/Akt signalling in skeletal muscle of young men with low birth weight

Christine B Jensen, Malgorzata S Martin-Gronert, Heidi Storgaard, Sten Madsbad, Allan Vaag, Susan E Ozanne, Christine B Jensen, Malgorzata S Martin-Gronert, Heidi Storgaard, Sten Madsbad, Allan Vaag, Susan E Ozanne

Abstract

Background: Low birth weight (LBW) is associated with increased future risk of insulin resistance and type 2 diabetes mellitus. The underlying molecular mechanisms remain poorly understood. We have previously shown that young LBW men have reduced skeletal muscle expression of PI3K p85alpha regulatory subunit and p110beta catalytic subunit, PKCzeta and GLUT4 in the fasting state. The aim of this study was to determine whether insulin activation of the PI3K/Akt and MAPK signalling pathways is altered in skeletal muscle of young adult men with LBW.

Methods: Vastus lateralis muscle biopsies were obtained from 20 healthy 19-yr old men with BW< or = 10th percentile for gestational age (LBW) and 20 normal birth weight controls (NBW), matched for physical fitness and whole-body glucose disposal, prior to (fasting state) and following a 4-hr hyperinsulinemic euglycemic clamp (insulin stimulated state). Expression and phosphorylation of selected proteins was determined by Western blotting.

Principal findings: Insulin stimulated expression of aPKCzeta (p<0.001) and Akt1 (p<0.001) was decreased in muscle of LBW men when compared to insulin stimulated controls. LBW was associated with increased insulin stimulated levels of IRS1 (p<0.05), PI3K p85alpha (p<0.001) and p110beta (p<0.05) subunits, while there was no significant change in these proteins in insulin stimulated control muscle. In addition LBW had reduced insulin stimulated phospho-Akt (Ser 473) (p<0.01), indicative of reduced Akt signalling. Insulin stimulated expression/phosphorylation of all the MAPK proteins studied [p38 MAPK, phospho-p38 MAPK (Thr180/Tyr182), phospho-ERK (Thr 202/Tyr204), JNK1, JNK2 and phospho-JNK (Thr 183/Tyr185)] was not different between groups.

Conclusions: We conclude that altered insulin activation of the PI3K/Akt but not the MAPK pathway precedes and may contribute to development of whole-body insulin resistance and type 2 diabetes in men with LBW.

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Figures

Figure 1. Expression and phosphorylation of key…
Figure 1. Expression and phosphorylation of key proteins involved in PI3K signalling.
Bars represent mean basal and insulin-stimulated (INS) expression values±SEM for low birth weight (LBW) and control (CON) individuals, expressed as % of mean control. Representative blots of the respective proteins are located below the corresponding bar graphs. *p<0.05, **p<0.01, ***p<0.001.

References

    1. Gluckman PD, Hanson MA, Beedle AS. Early life events and their consequences for later disease: a life history and evolutionary perspective. Am J Hum Biol. 2007;19:1–19.
    1. McMillen IC, Robinson JS. Developmental origins of the metabolic syndrome: prediction, plasticity, and programming. Physiol Rev. 2005;85:571–633.
    1. DeFronzo RA, Gunnarsson R, Bjorkman O, Olsson M, Wahren J. Effects of insulin on peripheral and splanchnic glucose metabolism in noninsulin-dependent (type II) diabetes mellitus. J Clin Invest. 1985;76:149–155.
    1. Martin BC, Warram JH, Krolewski AS, Bergman RN, Soeldner JS, et al. Role of glucose and insulin resistance in development of type 2 diabetes mellitus: results of a 25-year follow-up study. Lancet. 1992;340:925–929.
    1. Kensara OA, Wootton SA, Phillips DI, Patel M, Jackson AA, et al. Fetal programming of body composition: relation between birth weight and body composition measured with dual-energy X-ray absorptiometry and anthropometric methods in older Englishmen. Am J Clin Nutr. 2005;82:980–987.
    1. Jensen CB, Storgaard H, Madsbad S, Richter EA, Vaag AA. Altered Skeletal Muscle Fiber Composition and Size Precede Whole-body Insulin Resistance in Young Men with Low Birth Weight. J Clin Endocrinol Metab. 2007;92:1530–1534.
    1. Hermann TS, Rask-Madsen C, Ihlemann N, Dominguez H, Jensen CB, et al. Normal insulin-stimulated endothelial function and impaired insulin-stimulated muscle glucose uptake in young adults with low birth weight. J Clin.Endocrinol Metab. 2003;88:1252–1257.
    1. Ozanne SE, Jensen CB, Tingey KJ, Storgaard H, Madsbad S, et al. Low birthweight is associated with specific changes in muscle insulin-signalling protein expression. Diabetologia. 2005;48:547–552.
    1. Taniguchi CM, Emanuelli B, Kahn CR. Critical nodes in signalling pathways: insights into insulin action. Nat Rev Mol Cell Biol. 2006;7:85–96.
    1. Koistinen HA, Chibalin AV, Zierath JR. Aberrant p38 mitogen-activated protein kinase signalling in skeletal muscle from Type 2 diabetic patients. Diabetologia. 2003;46:1324–1328.
    1. Zarubin T, Han J. Activation and signaling of the p38 MAP kinase pathway. Cell Res. 2005;15:11–18.
    1. Miller BS, Shankavaram UT, Horney MJ, Gore AC, Kurtz DT, et al. Activation of cJun NH2-terminal kinase/stress-activated protein kinase by insulin. Biochemistry. 1996;35:8769–8775.
    1. Furtado LM, Somwar R, Sweeney G, Niu W, Klip A. Activation of the glucose transporter GLUT4 by insulin. Biochem Cell Biol. 2002;80:569–578.
    1. Lee YH, Giraud J, Davis RJ, White MF. C-Jun N-terminal kinase (JNK) mediates feedback inhibition of the insulin signaling cascade. J Biol Chem. 2003;278:2896–2902.
    1. Jensen CB, Storgaard H, Dela F, Holst JJ, Madsbad S, et al. Early differential defects of insulin secretion and action in 19-year- old Caucasian men who had low birth weight. Diabetes. 2002;51:1271–1280.
    1. Farese RV, Sajan MP, Standaert ML. Insulin-sensitive protein kinases (atypical protein kinase C and protein kinase B/Akt): actions and defects in obesity and type II diabetes. Exp Biol Med (Maywood) 2005;230:593–605.
    1. Ozanne SE, Jensen CB, Tingey KJ, Martin-Gronert MS, Grunnet L, et al. Decreased protein levels of key insulin signalling molecules in adipose tissue from young men with a low birthweight-potential link to increased risk of diabetes? Diabetologia. 2006;49:2993–2999.
    1. Huang C, Thirone AC, Huang X, Klip A. Differential contribution of insulin receptor substrates 1 versus 2 to insulin signaling and glucose uptake in l6 myotubes. J Biol Chem. 2005;280:19426–19435.
    1. Bouzakri K, Zachrisson A, Al-Khalili L, Zhang BB, Koistinen HA, et al. siRNA-based gene silencing reveals specialized roles of IRS-1/Akt2 and IRS-2/Akt1 in glucose and lipid metabolism in human skeletal muscle. Cell Metab. 2006;4:89–96.
    1. Bjornholm M, Kawano Y, Lehtihet M, Zierath JR. Insulin receptor substrate-1 phosphorylation and phosphatidylinositol 3-kinase activity in skeletal muscle from NIDDM subjects after in vivo insulin stimulation. Diabetes. 1997;46:524–527.
    1. Ruiz-Alcaraz AJ, Liu HK, Cuthbertson DJ, McManus EJ, Akhtar S, et al. A novel regulation of IRS1 (insulin receptor substrate-1) expression following short term insulin administration. Biochem J. 2005;392:345–352.
    1. Ueki K, Fruman DA, Yballe CM, Fasshauer M, Klein J, et al. Positive and negative roles of p85 alpha and p85 beta regulatory subunits of phosphoinositide 3-kinase in insulin signaling. J Biol Chem. 2003;278:48453–48466.
    1. Mauvais-Jarvis F, Ueki K, Fruman DA, Hirshman MF, Sakamoto K, et al. Reduced expression of the murine p85alpha subunit of phosphoinositide 3-kinase improves insulin signaling and ameliorates diabetes. J Clin Invest. 2002;109:141–149.
    1. Bandyopadhyay GK, Yu JG, Ofrecio J, Olefsky JM. Increased p85/55/50 expression and decreased phosphotidylinositol 3-kinase activity in insulin-resistant human skeletal muscle. Diabetes. 2005;54:2351–2359.
    1. Barbour LA, Mizanoor RS, Rahman S, Gurevich I, Leitner JW, et al. Increased P85alpha is a potent negative regulator of skeletal muscle insulin signaling and induces in vivo insulin resistance associated with growth hormone excess. J Biol Chem. 2005;280:37489–37494.
    1. Cornier MA, Bessesen DH, Gurevich I, Leitner JW, Draznin B. Nutritional upregulation of p85alpha expression is an early molecular manifestation of insulin resistance. Diabetologia. 2006;49:748–754.
    1. Luo J, Field SJ, Lee JY, Engelman JA, Cantley LC. The p85 regulatory subunit of phosphoinositide 3-kinase down-regulates IRS-1 signaling via the formation of a sequestration complex. J Cell Biol. 2005;170:455–464.
    1. Krook A, Roth RA, Jiang XJ, Zierath JR, Wallberg-Henriksson H. Insulin-stimulated Akt kinase activity is reduced in skeletal muscle from NIDDM subjects. Diabetes. 1998;47:1281–1286.
    1. Cozzone D, Frojdo S, Disse E, Debard C, Laville M, et al. Isoform-specific defects of insulin stimulation of Akt/protein kinase B (PKB) in skeletal muscle cells from type 2 diabetic patients. Diabetologia. 2008;51:512–521.
    1. Kroook A, Kawano Y, Song XM, Efendić S, Roth RA, et al. Improved glucose tolerance restores insulin-stimulated Akt kinase activity and glucose transport in skeletal muscle from diabetic Goto-Kakizaki rats. Diabetes. 1997;46:2110–2114.
    1. Altomare DA, Lyons GE, Mitsuuchi Y, Cheng JQ, Testa JR. Akt2 mRNA is highly expressed in embryonic brown fat and the AKT2 kinase is activated by insulin. Oncogene. 1998;16:2407–2411.
    1. Altomare DA, Guo K, Cheng JQ, Sonoda G, Walsh K, et al. Cloning, chromosomal localization and expression analysis of the mouse Akt2 oncogene. Oncogene. 1995;11:1055–1060.
    1. Bouzakri K, Zachrisson A, Al-Khalili L, Zhang BB, Koistinen HA, et al. siRNA-based gene silencing reveals specialized roles of IRS-1/Akt2 and IRS-2/Akt1 in glucose and lipid metabolism in human skeletal muscle. Cell Metab. 2006;4:89–96.
    1. Kotani K, Ogawa W, Matsumoto M, Kitamura T, Sakaue H, et al. Requirement of atypical protein kinase clambda for insulin stimulation of glucose uptake but not for Akt activation in 3T3–L1 adipocytes. Mol Cell Biol. 1998;18:6971–6982.
    1. Sajan MP, Rivas J, Li P, Standaert ML, Farese RV. Repletion of Atypical Protein Kinase C following RNA Interference-mediated Depletion Restores Insulin-stimulated Glucose Transport. J Biol Chem. 2006;281:17466–17473.
    1. Standaert ML, Galloway L, Karnam P, Bandyopadhyay G, Moscat J, et al. Protein kinase C-zeta as a downstream effector of phosphatidylinositol 3-kinase during insulin stimulation in rat adipocytes: potential role in glucose transport. J Biol Chem. 1997;272:30075–30082.
    1. Bandyopadhyay G, Kanoh Y, Sajan MP, Standaert ML, Farese RV. Effects of adenoviral gene transfer of wild-type, constitutively active, and kinase-defective protein kinase C-lambda on insulin-stimulated glucose transport in L6 myotubes. Endocrinology. 2000;141:4120–4127.
    1. Bandyopadhyay G, Standaert ML, Galloway L, Moscat J, Farese RV. Evidence for involvement of protein kinase C (PKC)-zeta and noninvolvement of diacylglycerol-sensitive PKCs in insulin-stimulated glucose transport in L6 myotubes. Endocrinology. 1997;138:4721–4731.
    1. Etgen GJ, Valasek KM, Broderick CL, Miller AR. In vivo adenoviral delivery of recombinant human protein kinase C-zeta stimulates glucose transport activity in rat skeletal muscle. J Biol Chem. 1999;274:22139–22142.
    1. Kim YB, Kotani K, Ciaraldi TP, Henry RR, Kahn BB. Insulin-stimulated protein kinase C lambda/zeta activity is reduced in skeletal muscle of humans with obesity and type 2 diabetes: reversal with weight reduction. Diabetes. 2003;52:1935–1942.
    1. Beeson M, Sajan MP, Dizon M, Grebenev D, Gomez-Daspet J, et al. Activation of protein kinase C-zeta by insulin and phosphatidylinositol-3,4,5-(PO4)3 is defective in muscle in type 2 diabetes and impaired glucose tolerance: amelioration by rosiglitazone and exercise. Diabetes. 2003;52:1926–1934.
    1. Oak SA, Tran C, Pan G, Thamotharan M, Devaskar SU. Perturbed skeletal muscle insulin signaling in the adult female intrauterine growth-restricted rat. Am J Physiol Endocrinol Metab. 2006;290:E1321–E1330.
    1. Andersen PH, Lund S, Vestergaard H, Junker S, Kahn BB, et al. Expression of the major insulin regulatable glucose transporter (GLUT4) in skeletal muscle of noninsulin-dependent diabetic patients and healthy subjects before and after insulin infusion. J Clin Endocrinol Metab. 1993;77:27–32.
    1. Handberg A, Vaag A, Beck-Nielsen H, Vinten J. Peripheral glucose uptake and skeletal muscle GLUT4 content in man: effect of insulin and free fatty acids. Diabet Med. 1992;9:605–610.
    1. Thamotharan M, Shin BC, Suddirikku DT, Thamotharan S, Garg M, et al. GLUT4 expression and subcellular localization in the intrauterine growth-restricted adult rat female offspring. Am J Physiol Endocrinol Metab. 2005;288:E935–E947.
    1. Huang C, Somwar R, Patel N, Niu W, Torok D, et al. Sustained exposure of L6 myotubes to high glucose and insulin decreases insulin-stimulated GLUT4 translocation but upregulates GLUT4 activity. Diabetes. 2002;51:2090–8.

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner